Loading...
Market
What will be the public perception of lifespan-extending drugs for pets by the end of 2025?
2
Resolution / Starting Odds
Widely accepted and positive • 25%
Cautiously optimistic • 25%
Skeptical or negative • 25%
Largely indifferent • 25%
Surveys or studies published by market research firms or academic institutions
Story
Scientists Develop Drugs, Including mTOR Inhibitor Rapamycin, to Extend Lifespan of Dogs with Implications for Human Longevity
Dec 27, 2024, 05:42 AM
Researchers are exploring new drugs aimed at extending the lifespan of dogs, which may have implications for human longevity. Current studies focus on the development of a pill that could prolong the lives of dogs, with scientists suggesting that similar effects might be applicable to humans. This follows the previous identification of the mTOR inhibitor, Rapamycin, as the only molecule rigorously proven to increase lifespan in healthy mice across various studies. The ongoing research into canine longevity could pave the way for advancements in human health and lifespan extension.
View original story
Similar markets
No change in affordability perception • 25%
Worsening perception of affordability • 25%
Significant improvement in affordability perception • 25%
Slight improvement in affordability perception • 25%
No significant change • 25%
Less supportive of a ban • 25%
More supportive of a ban • 25%
Other opinion shift • 25%
Mostly positive • 25%
Indifferent • 25%
Mixed • 25%
Mostly negative • 25%
More negative • 25%
Unchanged • 25%
More positive • 25%
Mixed opinions • 25%
More favorable • 25%
No change • 25%
Uncertain • 25%
Less favorable • 25%
Increase in support • 25%
Decrease in support • 25%
No change • 25%
Mixed opinions • 25%
Publicly criticized • 25%
Very effective • 25%
Not effective • 25%
Somewhat effective • 25%
Major public protests • 25%
Mixed reactions • 25%
Predominantly negative • 25%
Widespread support • 25%
Unchanged • 25%
Mostly positive • 25%
Mixed • 25%
Mostly negative • 25%
Majority support • 25%
Majority oppose • 25%
Evenly divided • 25%
Low awareness • 25%
Significantly positive • 25%
Negative • 25%
Neutral • 25%
Moderately positive • 25%
Majority supportive • 25%
Majority opposed • 25%
Evenly split • 25%
No significant response • 25%